AEPBI
NAUT icon

AH Equity Partners Bio II’s Nautilus Biotechnolgy NAUT Stock Holding History

AH Equity Partners Bio II’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$34.6M Hold
16,298,006
– – 24.08% 2
2022
Q2 		$43.8M Hold
16,298,006
– – 30.79% 2
2022
Q1 		$70.7M Hold
16,298,006
– – 40.75% 2
2021
Q4 		$16.3M Buy
+16,298,006
New +$87.2M 8.49% 4

Other funds holding NAUT

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MVG
Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.01B AUM 2.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
AI
ArchPoint Investors Coral Gables, Florida $420M AUM 42.19% 1-Year Est. Return
AEPLI
AH Equity Partners LSV II Menlo Park, California $95.6M AUM 8.86% 1-Year Est. Return

AH Equity Partners Bio II's NAUT Position: Q3 2022 in Review

AH Equity Partners Bio II held its Nautilus Biotechnolgy (NAUT) position steady in Q3 2022 at 16,298,006 shares worth $34.6M. The position accounts for 24.08% of the portfolio, ranked #2.

AH Equity Partners Bio II first reported a position in NAUT in Q4 2021 and has held it in 4 quarters since. The position peaked at $70.7M in Q1 2022. 86 funds tracked by Wall St. Rank hold NAUT as of Q3 2022.

  • AH Equity Partners Bio II held 16,298,006 shares of Nautilus Biotechnolgy worth $34.6M as of Q3 2022.
  • AH Equity Partners Bio II left its Nautilus Biotechnolgy share count unchanged in Q3 2022.
  • Nautilus Biotechnolgy made up 24.08% of AH Equity Partners Bio II's portfolio in Q3 2022, its #2 holding.
  • AH Equity Partners Bio II first reported a position in Nautilus Biotechnolgy in Q4 2021 and has held it in 4 quarters since.
  • AH Equity Partners Bio II's Nautilus Biotechnolgy position peaked at $70.7M in Q1 2022.
  • 86 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q3 2022.

Based on AH Equity Partners Bio II's 13F filing for Q3 2022, filed 14 Nov 2022.